Acute myeloid leukemia (AML) is a clinically and molecularly heterogeneous disease with poor outcome. Adequate model systems are required for preclinical studies to improve understanding of AML biology and to develop novel. rational treatment approaches. Xenografts in immunodeficient mice allow performing functional studies on patient-derived AML cells. https://www.bekindtopets.com/